We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences Inc.’s stock climbed 3% early Thursday after the company said its twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, building the case for ...

Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the ...

Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.

Originally published by Gilead Sciences View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $95.00.

Gilead Sciences rose 2% in early trading, after the biotech reported positive data for a long-acting HIV prevention drug that promises to be a big seller. The drug, called lenacapavir, was 96% ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture with Fosun Pharma.

Chris Schott has given his Buy rating due to a combination of factors revolving around Gilead Sciences’ drug, lenacapavir, and its potential impact on the market. Schott points out the ...

View Gilead Sciences, Inc. (GILD) current and estimated P/E ratio data provided by Seeking Alpha.

By Rebecca Robbins and Sheryl Gay Stolberg A jury sided with Gilead Sciences in a dispute over whether the government could claim a share of profits from drugs seen as crucial to ending the H.I.V ...